



Common Drug Review *

Submission Status

| | | | |
|----------------------------------|---|---------------------------------|--|
| Product: | <input type="text" value="Forteo"/> | | |
| Generic Name: | <input type="text" value="teriparatide (rDNA origin) injection"/> | | |
| Manufacturer: | <input type="text" value="Eli Lilly Canada Inc."/> | | |
| Submission Type: | <input type="text" value="Resubmission #2"/> | | |
| Date Submission Received: | <input type="text" value="2008-Dec-18"/> | Date NOC Issued: | <input type="text" value="2004-Jun-03"/> |
| Targeted CEDAC Meeting: | <input type="text"/> | Priority Review Granted: | <input type="text" value="Not Requested"/> |

| | Phase | Target Time (Business Days) | Target Date** | Actual CDR Date | Comments |
|-------|--|-----------------------------------|---------------|-----------------|---|
| 1 | Submission Assessment | 10 | 2009-Jan-09 | | Additional information requested January 14, 2009. Additional information received January 15, 2009. |
| | Submission deemed complete | | | N/A | Withdrawn at request of manufacturer, January 21, 2009. |
| 2 | CDR Reviewers' Reports Completed <ul style="list-style-type: none"> • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer | 45 | | N/A | |
| 3 | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7 | | N/A | |
| 4 | Reviewers' Reply to Manufacturer's Comments Completed | 7 | | N/A | |
| 5 | CEDAC Brief Completed and Sent to CEDAC Members | 5 | | N/A | |
| 6 | CEDAC Meeting | | | | |
| 7 | CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer | 5 | | | |
| 8 | Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10 | | | |
| 9 (a) | Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5 | | | |
| OR | | | | | |
| 9 (b) | Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made) | 5 | | | |
| OR | | | | | |
| 9 (c) | Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request) | 25 Depends on Meeting Dates | | | |
| 10 | Final Recommendation sent to Drug Plans, ACP, and Manufacturer | 5 | | | |

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.